The FDA approved the use of an immune checkpoint inhibitor as a first-line treatment for patients with colorectal cancers caused by genetic mutations that stem from an inability to repair mistakes or damage in DNA coding.
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with cutaneous squamous cell carcinoma.
The FDA has approved a targeted therapy drug to treat certain adult patients with diffuse large B-cell lymphoma.
The FDA approved the use of a companion diagnostic to identify patients with tumors that have large numbers of genetic mutations.
The FDA approved an analog of a marine compound to treat certain patients with small cell lung cancer.
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with a common form of esophageal cancer.
The FDA approved a combination of an immunotherapy and a therapeutic that can stop tumors from growing blood vessels for certain patients with liver cancer.
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has expanded the use of...
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors.
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with prostate cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More